The Denosumab for Type 1 Diabetes phase 1/2 clinical trial, is a collaborative study with the Arthur Riggs Diabetes and Metabolism Research Institute and the Center for Diabetes and Metabolic Diseases at Indiana University.

Many people, including clinicians and researchers, think “the main reason people regain weight after weight loss is because the body fights back” in a phenomenon called metabolic adaptation, said UAB researcher Cátia Martins, Ph.D. Martins, a leading scientist studying metabolic adaptation, explains what she has found and her plans for a groundbreaking clinical trial.

Continuous glucose monitors and insulin pumps can help patients “live a quality life without burning out on managing diabetes,” said Ananda Basu, M.D., director of the Diabetes Technology Program at UAB.

Continuous glucose monitors are “such a useful and impactful behavior modification tool” that half of his patients with Type 1 and Type 2 diabetes now use these devices, said Fernando Ovalle, M.D., director of UAB’s Multidisciplinary Comprehensive Diabetes Clinic. Learn how data leads to better decisions and better control of diabetes.

Anath Shalev, M.D., did everything she could to change treatment for Type 1 diabetes from her lab, but getting to first-in-human trials meant taking a step she had always resisted. The most surprising thing about launching a startup, though? “I have enjoyed it.”

John Kearney, Ph.D., Distinguished Professor in the Department of Microbiology, will be honored for 45 years of service to UAB during the annual Service Awards banquet March 6.